Verastem Oncology Reports Durable Efficacy in LGSOC Therapy at Two-Year Mark
Event summary
- Two-year median follow-up data from the Phase 2 RAMP 201 trial shows durable efficacy of AVMAPKI® FAKZYNJA® combination therapy in recurrent low-grade serous ovarian cancer (LGSOC).
- Median duration of response (mDOR) maintained at 31.1 months for KRAS-mutated patients, with 50% remaining on therapy for over one year.
- Safety profile remains consistent with primary analysis, with a 12% discontinuation rate due to adverse events.
- Exposure-response analysis confirms optimal therapeutic effect at FDA-approved dosing, with manageable toxicity through dose interruptions.
The big picture
Verastem Oncology's two-year data reinforces the potential of its AVMAPKI® FAKZYNJA® combination therapy as a durable treatment option for recurrent LGSOC, a rare and challenging cancer with limited therapeutic options. The results come at a critical juncture as Verastem seeks to solidify its position in the oncology space, particularly in RAS/MAPK pathway-driven cancers. The manageable safety profile and long-term efficacy data could differentiate the therapy in a competitive landscape, though the company must navigate the regulatory pathway to secure full approval.
What we're watching
- Clinical Validation
- Whether the durable efficacy data will accelerate adoption of AVMAPKI® FAKZYNJA® in the LGSOC treatment landscape.
- Regulatory Pathway
- The pace at which Verastem can secure full FDA approval contingent upon confirmatory trial results.
- Commercial Strategy
- How Verastem will position the combination therapy against existing MEK-based approaches in the recurrent LGSOC market.
Related topics